Will my privacy be protected?

All personal and medical information will be kept strictly confidential. Information about your health while you are enrolled in the YORVIPATH Lactation Safety Study will be kept anonymous and any identifying information will not be used.

Risks/Benefits:

YORVIPATH is an FDA-approved treatment for hypoparathyroidism in adults. However, there is not enough information yet to establish the safety of Yorvipath in pregnancy. This registry helps gather important information about its use during and after pregnancy to better understand effects on mothers and babies. For more information on YORVIPATH please refer to the prescribing information that comes with your medication.

To speak to a study representative, contact the YORVIPATH Lactation Safety Study toll-free at: 877-229-2184 M-F, 8-8 ET or via email at Yorvipathlactation@ubc.com.

For more information visit:
www.YORVIPATHregistry.com

ascendis pharma

MED-US-TC-PTH-2500156
01/2026

YourLifePath
LACTATION STUDY

Patient Brochure

YORVIPATH Lactation Safety Study

This study is being done to see how much YORVIPATH (palopegteriparatide) passes into breast milk in women who are breastfeeding while taking this drug.

This is an observational study which means you and your baby will continue to receive the usual medical care from your own doctors.

No mandatory clinic visits are required; however, you must agree to a 24-hour collection period of your breast milk and agree to two home visits by the study nurse.

Why should I participate in this study?

Your participation is voluntary but may help doctors and researchers better understand the safety of YORVIPATH. Additionally, data from this registry may help guide future care for pregnant and lactating women and their babies.

You may be compensated up to $500 for your time and participation.

YourLifePath
LACTATION STUDY

Who can participate in the study?

- Women 18 years or older, receiving YORVIPATH as part of their routine medical care and taking the same dose for a minimum of 14 days
- Women who have also agreed to take part in the YORVIPATH Pregnancy Safety Study
- Women who are breastfeeding where breast milk is the main source of nutrition for their infant(s)

What to expect?

A study nurse will visit you twice at your home at times that work best for you. During the first visit, they will review the breast pumping procedures, as well as cover the breast milk collection intervals, milk measurement and storage, sample collection and labeling.

The second visit will happen 12 to 16 hours after your 24-hour breast milk collection period has ended. At this visit, the study nurse will gather the samples for shipment.

Before the collection starts, your baby's main source of nutrition should be breast milk. During this time, you may give up to one small bottle of formula each day (no more than 8 oz).

During the 24-hour collection period, you may use as much supplemental formula as needed.

A shipment of study supplies will be sent to your home, including a medical grade electric breast pump (yours to keep), a digital scale for weighing your breast milk collection, containers and a cooler.

How do I enroll?

To learn more about the YORVIPATH Lactation Safety Study and to find out if you are eligible for enrollment, contact a study representative at **877-229-2184**, or visit the study website at: YORVIPATHregistry.com. You may also ask your doctor to enroll you.

If you are eligible and decide to take part, you will be asked to review and sign an informed consent form. This form shows that you understand the study and agree to participate. This provides your permission for your personal and infant's healthcare information to be collected. After consent is received a study representative will contact your doctor to confirm your personal health information.